Results:
MAT was related to radiation-induced expression changes of four of the considered genes in fibroblasts. The strongest impact was obtained for SMAD7 and CAT at d5. The higher the MAT score, the lower the induction of SMAD7 and CAT by radiation was (p= 0.001 and 0.003). However, upon the wash-out period at d12 no statistical differences in dependence on the MAT score were seen anymore for these two genes. In contrast, a high MAT score was linked to low radiation-induced induction of CTGF (p=0.005) and to a faster decrease of the massively induced CDKN1A (p= 0.03) at d12. At d2, a trend (p= 0.06) for CAT in relation to MAT in the same direction as at d5 was noticed with no correlation of any of the other genes at this early time point.
Conclusion:
Radiation-induced expression changes in patientmatched fibroblasts may serve as biomarkers to predict clinical radiotoxicity. Induction of SMAD7 and CAT may mitigate TGFbeta signalling and reactive oxygen species load thus saving normal tissue during radiotherapy. A protective role might also be attributed to sustained elevation of CDKN1A. The link between post-radiation induction of CTGF in fibroblasts and low MAT remains to be clarified. Understanding the mechanistic basis of these findings might pave the way for better protection of irradiated normal tissue. Purpose or Objective: Erectile dysfunction (ED) is one of the most common complications encountered after radiotherapy in prostate cancer patients. The goal of this study was to investigate whether single nucleotide polymorphisms (SNPs) are associated with late ED in men treated with radiotherapy for prostate cancer. To this end, we designed a novel machine learning-based multi-SNP model using a genomewide association study (GWAS) dataset.
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Material and Methods:
We analyzed 236 evaluable patients with at least one year of follow-up for the development of ED. The severity of ED was assessed using either the patientadministered Sexual Health Inventory for Men (SHIM) or the clinician-assigned Mount Sinai Erectile Function (MSEF) scoring schema. There were 133 patients with Grade 2 or more ED. For our analysis, the cohort was split into two groups (cases/controls: MSEF 0,1 / 2,3; cases/controls: SHIM ≤7 / ≥16). Genome-wide SNP data were available from Affymetrix Genome-Wide Human SNP Array 6.0. After a quality test including SNP missing rate>5%, minor allele frequency (MAF)<5%, and Hardy-Weinberg equilibrium (p<10E-5), 613,496 SNPs remained. For the validation purpose of our proposed model, the dataset was split into a training dataset (2/3 of samples) and a validation dataset (1/3 of samples). Our model building process was performed using the bootstrapped data from the training dataset. Our idea is to convert the binary outcomes into preconditioned continuous outcomes based on normal tissue complication probability (NTCP) using principal component analysis (PCA) and logistic regression. The preconditioned outcomes were used in the model building process using random forest regression. Then, the model was tested using the validation dataset. The final predicted outcomes were compared with the original binary outcomes to estimate the predictive performance. We iterated this process 100 times and the performance was averaged. We compared the performance of our proposed method (preconditioning random forest regression: PRFR) with other methods including preconditioning lasso (PL), lasso logistic regression (LLR), and random forest classification (RFC).
Results: Univariate analysis was performed using the training dataset. With a threshold of p= 0.001, 367 SNPs remained. These SNPs were fed into our model. As shown in Figure (A) , the averaged performance with the validation dataset was AUC= 0.62, which is better than other methods: RFC (0.57), PL (0.58), and LLR (0.57). The 79 patients in the validation dataset were binned into 6 groups according to the predicted risk of ED. Figure (B) shows the comparison of the modelpredicted incidence of ED with observed incidence.
Conclusion:
Our machine learning-based multi-SNP model showed the potential to better predict the radiation-induced late ED. However, we need to validate our model using other datasets.
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ESTRO 35 2016 _____________________________________________________________________________________________________ fractionated radiation treatment is assumed to be decisive for treatment success. [18F]-Fluoro-Misonidazole PET (F-MISO-PET) allows noninvasive assessment of hypoxia during treatment. The purpose of the present study was to noninvasively assess the time course of tumor hypoxia.
Material and Methods:
A prospective serial imaging study was conducted in patients undergoing definitive chemoradiation (dRCTx, total dose 70Gy) for locally advanced HNSCC, accompanied by cisplatin in weeks 1, 4 and 7. Tumor hypoxia was assessed by F-MISO-PET by static scans acquired 2.5 h p.i. Tumor volumes were determined for FDG PET/CT scans and the coregistered F-MISO/CT scans. At baseline MRI, FDG-PET/CT and F-MISO-PET were acquired (week 0). Additional F-MISO-PET/CT scans were acquired in treatment weeks 2 and 5. Normal sample distribution was confirmed with Shapiro-Wilk test. Unpaired t-test analysis of the mean SUVmax(tumor)/SUVmean(muscle) ratios of F-MISO-PET in weeks 0, 2 and 5 were performed. Significance-level was defined as p<0.005.
Results: Between 2012 and 2014 18 patients (16 men, two women, mean age 60 years), treated for HNSCC with dRCTx were included. All received a total dose of 70 Gy in 35 fractions. Concomitant cisplatin chemotherapy was administered in weeks 1, 4 and 7. 14 patients had all F-MISO-PET scans, while 4 had two F-MISO-PET scans (week 0, 5). The mean follow-up time was 14.6 months (range: 4 -28 months). Mean SUVmax(tumor)/SUVmean(muscle) in weeks 0, 2 and 5 were 1.9 (n= 18, SD ± 0.1), 1.5 (n= 14, SD ± 0.1) and 1.2 (n= 18, SD ± 0.1), respectively. Unpaired t-test for SUVmax(tumor)/SUVmean(muscle) between week 0 and 5 was performed, showing a singnificant decrease (p<0.0001). Between weeks 0 and 2 (p=0.0346) and between weeks 2 and 5 the decrease again was highly significant (p=0.0113). In two patients no residual hypoxia was measured in week two, resulting in SUVmax(tumor)/SUVmean(muscle) = 1.0. In week 5 this was found in seven patients. In two patients hypoxia had increased in week 2 but decreased in week 5 compared to pre-treatment measurements. In one patient hypoxia had increased by the end of treatment.
Conclusion:
Differences in hypoxia between weeks 0-2, 2-5 and 0-5, respectively, show statistical significance. This is crucial in the process of re-oxygenation. As concluded in previous works, change of treatment strategy, e.g. by means of dose escalation might be most efficient early during treatment. However further analysis, with more patients and correlation to disease-free and overall-survival are needed.
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